DuPont starts TACE inhibitor Phase II

DuPont Pharmaceuticals (Wilmington, Del.) began North American and European Phase II testing of its oral inhibitor of tumor necrosis factor alpha converting enzyme (TACE) to treat rheumatoid arthritis...